Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493441 · ClinicalTrials.gov registry record · Phase 2
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00493441 is a Phase 2 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 28 participants.
The verdict
NCT00493441, a Phase 2 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
Interventions
- DRUG AVN944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493441
The ClinicalTrials.gov registry entry for NCT00493441 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVN944 is the first listed.
NCT00493441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493441 about?
NCT00493441 is a clinical study titled "AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer". The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
What is the current status of trial NCT00493441?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00493441?
The interventions under investigation include: AVN944 (DRUG).
Who is sponsoring clinical trial NCT00493441?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.